180 related articles for article (PubMed ID: 9700659)
1. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
6. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.
Formichi P; Battisti C; Radi E; Federico A
J Cell Physiol; 2006 Jul; 208(1):39-46. PubMed ID: 16447254
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
9. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease.
Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P
Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336
[TBL] [Abstract][Full Text] [Related]
10. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
[TBL] [Abstract][Full Text] [Related]
12. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
15. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
[TBL] [Abstract][Full Text] [Related]
16. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42).
Kaiser E; Schönknecht P; Thomann PA; Hunt A; Schröder J
Neurosci Lett; 2007 May; 417(2):193-5. PubMed ID: 17408854
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Maruyama M; Arai H; Sugita M; Tanji H; Higuchi M; Okamura N; Matsui T; Higuchi S; Matsushita S; Yoshida H; Sasaki H
Exp Neurol; 2001 Dec; 172(2):433-6. PubMed ID: 11716567
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
20. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
